Table 1.
Baseline characteristics
| All patients N = 119 (%) | IB CR + PR N = 69 (%) | IB SD N = 35 (%) | IB PD N = 15 (%) | p value | |
|---|---|---|---|---|---|
| Median age at diagnosis in years (range) | 64 (23–90) | 66 (23–90) | 63 (40–86) | 64 (38–89) | 0.67 |
| Median age at ibrutinib therapy in years (range) | 68 (27–91) | 69 (27–90) | 67 (42–86) | 65 (41–91) | 0.74 |
| Gender | 0.89 | ||||
| Male | 55 (46) | 33 (48) | 15 (43) | 7 (47) | |
| Female | 64 (54) | 36 (52) | 20 (57) | 8 (53) | |
| BMI | 0.95 | ||||
| < 30 | 71 (71) | 43 (72) | 20 (69) | 8 (73) | |
| ≥ 30 | 29 (29) | 17 (28) | 9 (31) | 3 (27) | |
| Missing | 19 | 9 | 6 | 4 | |
| ECOG PS at diagnosis | 0.53 | ||||
| 0 | 46 (46.5) | 25 (42) | 13 (50) | 8 (61) | |
| 1 | 47 (47.5) | 32 (53) | 11 (42) | 4 (31) | |
| ≥ 2 | 6 (6) | 3 (5) | 2 (8) | 1 (8) | |
| Missing | 20 | 9 | 9 | 2 | |
| MZL subtype | 0.97 | ||||
| NMZL | 50 (42) | 28 (41) | 17 (49) | 5 (33) | |
| SMZL | 29 (24) | 17 (25) | 8 (23) | 4 (27) | |
| EMZL | 40 (34) | 24 (34) | 10 (28) | 6 (40) | |
| Stage at diagnosis | 0.95 | ||||
| 1–2 | 19 (17) | 11 (16) | 6 (18) | 2 (14) | |
| 3–4 | 96 (83) | 56 (84) | 28 (82) | 12 (86) | |
| Missing | 4 | 2 | 1 | 1 | |
| B symptoms at diagnosis | 0.62 | ||||
| No | 81 (74) | 44 (70) | 25 (78) | 12 (80) | |
| Yes | 29 (26) | 19 (30) | 7 (22) | 3 (20) | |
| Missing | 9 | 6 | 3 | 0 | |
| LDH higher than institutional baseline | 0.80 | ||||
| No | 70 (71) | 43 (71) | 20 (74) | 7 (64) | |
| Yes | 29 (29) | 18 (29) | 7 (26) | 4 (36) | |
| Missing | 20 | 8 | 8 | 4 | |
| Albumin at diagnosis | 0.75 | ||||
| Normal | 80 (81) | 49 (80) | 22 | 9 | |
| Low | 19 (19) | 12 (20) | 4 | 3 | |
| Missing | 20 | 8 | 9 | 3 | |
| Monoclonal protein at diagnosis | 0.05 | ||||
| No | 49 (56) | 30 (54) | 17 (74) | 2 (25) | |
| Yes | 38 (44) | 26 (46) | 6 (26) | 6 (75) | |
| Missing | 32 | 13 | 12 | 7 | |
| BM involvement at diagnosis | 0.72 | ||||
| No | 32 (32) | 17 (30) | 10 (33) | 5 (42) | |
| Yes | 67 (68) | 40 (70) | 20 (67) | 7 (58) | |
| Not done | 20 | 11 | 5 | 3 | |
| TP53 mutation/17p deletion (n = 67)* | 0.99 | ||||
| No | 19 (28) | 10 (23) | 7 (47) | 2 (25) | |
| Yes | 10 (15) | 7 (16) | 2 (13) | 1 (13) | |
| Unavailable/not tested | 38 (57) | 27 (61) | 6 (40) | 5 (62) | |
| Complex cytogenetics (n = 67)* | 0.16 | ||||
| No | 57 (85) | 37 (90) | 17 (85) | 6 (67) | |
| Yes | 10 (15) | 4 (10) | 3 (15) | 3 (33) | |
| Primary refractory disease** | 0.07 | ||||
| No | 89 (75) | 56 (81) | 25 (71) | 8 (53) | |
| Yes | 30 (25) | 13 (19) | 10 (29) | 7 (47) | |
| First-line therapy | 0.47 | ||||
| Rituximab | 58 (49) | 35 (51) | 19 (54) | 4 (27) | |
| BR | 30 (25) | 16 (23) | 9 (26) | 5 (33) | |
| R-CVP | 11 (9) | 7 (10) | 1 (3) | 3 (20) | |
| R-CHOP | 9 (8) | 5 (7) | 2 (6) | 2 (13) | |
| Others | 11 (9) | 6 (9) | 4 (11) | 1 (7) | |
| Receipt of maintenance R | 0.27 | ||||
| No | 88 (74) | 47 (68) | 29 (83) | 12 (80) | |
| Yes | 31 (26) | 22 (32) | 6 (17) | 3 (20) | |
| Line of ibrutinib therapy | 0.40 | ||||
| Second line | 54 (45) | 31 (45) | 16 (46) | 7 (47) | |
| Third line | 41 (35) | 27 (39) | 9 (26) | 5 (33) | |
| Fourth line and beyond | 24 (20) | 11 (16) | 10 (28) | 3 (20) | |
| Median f/up in months (range)^ | 23 (1–75) | 23 (1–72) | 26 (3–75) | 6 (3–22) |
CR complete response, PR partial response, SD stable disease, PD progressive disease, BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, MZL marginal zone lymphoma, LDH lactate dehydrogenase, BM bone marrow, BR bendamustine rituximab, R-CVP rituximab, cyclophosphamide, vincristine, prednisone, R-CHOP rituximab, cyclophosphamide, Adriamycin, vincristine, prednisone, f/up follow-up
*Only among those who had bone marrow involvement. Complex karyotype was defined as the presence of at least three chromosomal aberrations in at least two cells
**Primary refractory disease: defined as progression of disease at the end of induction therapy or within 6 months of treatment completion. Among these 30 patients, 13 received rituximab, 9 received BR, 4 received R-CHOP, 3 received R-CVP, 1 received other
^Among those who are alive